Focal Questions of the Semashko Russian Pharmaceutical Forum
On 17-18 May, St. Petersburg saw one of the principal events of the industry – N.A. Semashko Russian Pharmaceutical Forum. More than 80 speakers and representatives of the regulatory authorities, pharmaceutical companies, and industry communities took part in the Forum over the two days of its work.
The Forum was inaugurated by Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of Russia, “Our objective now is to consolidate our joint endeavours to surmount the crisis that has arisen. The Forum is a perfect platform for building not only an inter-institutional dialogue but also a dialogue between the business and the government. It was the idea that formed the basis of the renewed concept of the Forum and gave it a new name, i.e. Nikolai Alexandrovich Semashko Russian Pharmaceutical Forum.”
The floor then was given to Oleg Ergashev, Vice Governor (Health care and Social Policy) of St. Petersburg, “Drug safety is our priority in today’s economic situation. St. Petersburg is a crucial cluster for the manufacture of medicinal products. 37% of the 800 vital and essential drugs are produced in St. Petersburg. And in the days ahead, we have to think about those foreign drugs to be replaced”.
Kirill Soloveichik, Chairman of the Committee for Industrial Policy, Innovations, and Trade of Saint Petersburg, joined the Forum, too. In his address, he noted that a working group was planned to be created, at the earliest possible time, for developing a drug safety policy in St. Petersburg, “We manufacture 427 International Non-proprietary Names, out of which 200 are included in the vital and essential drugs list. 152 items are to be substituted. We have all the tools for ramping up production. These include a special economic zone, tax concessions, and a scheme for the intended land grant”.
The Forum’s business programme started with an extensive plenary session that comprised two large sections. The first part of the plenary session featured presentations by heads of pharmaceutical companies who shared their vision of the status of the medicine procurement from the business viewpoint.
Representatives of the key establishments and industry communities continued the discussion in the second part of the plenary session. Welcome addresses to the Forum’s organizers and participants were extended by Mikhail Murashko, Minister of Health of the Russian Federation; Denis Manturov, Minister of the Industry and Trade of the Russian Federation; Inna Svyatenko, Chair of the Federation Committee on Social Policy; and Dmitry Khubezov, Chair of the State Duma Committee on Health Protection.
“We all are in the same boat – manufacturers of drugs and medical devices, suppliers of the APIs and consumables for medical equipment, distributors and logistics companies, as well as pharmacies. Our task is to hold an open dialogue”, Vladislav Shestakov, Director, FBI “State Institute of Drugs and Good Practices”, Russian Ministry of Industry and Trade, highlighted in his speech. In which he was supported by the co-moderator of the meeting, Executive Director of the Union of Professional Pharmaceutical Organizations, Lilia Titova, and Head of the Expert Council on the Circulation of Medicines and Medical Products of the State Duma Committee on Health Protection, Alexander Petrov.
“Trust of our citizens is a pivotal vector of our movement. Only through the continuous interaction and information exchange among all the stakeholders, we will be able to build a trust-based relationship with each and every patient and partner of ours,” Alexander Petrov emphasised.
- Cooperation issues in the pharmaceutical industry and healthcare system were discussed at the Russia-Africa Summit
- International cooperation discussed at the Drug Safety Forum
- Transformation of medical education and training of highly qualified personnel discussed at the Uzbek-Russian Medical Forum
- Memorandum of Cooperation signed between the Eurasian Academy of Good Practices, State Center for Expertise and Standardization of Medicines, Medical Devices and Medical Equipment (Uzbekistan), and Rusatom Healthcare JSC
- The prospects for the development of cooperation between Russia and Saudi Arabia in the pharmaceutical industry were discussed as part of the business mission Made in Russia + INNOPROM